CRISPR Therapeutics AG
CRSP: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$438.00 | Sps | Zcccdwqb |
CRISPR Therapeutics: Gene Editing Pipeline Continues to Make Progress; Shares Very Undervalued
CRISPR Therapeutics reported third-quarter results in line with our expectations, and its pipeline candidates are continuing to make progress. We maintain our positive outlook and fair value estimate of $119 per share. We view the stock as very undervalued, currently trading about 53% below our fair value estimate.